Europska Unija -
hrvatski -
EMA (European Medicines Agency)
zolsketil pegylated liposomal
accord healthcare s.l.u. - doxorubicin hydrochloride, liposomal - ovarian neoplasms; sarcoma, kaposi; multiple myeloma - doxorubicin - zolsketil pegylated liposomal is a medicine used to treat the following types of cancer in adults:• breast cancer that has spread to other parts of the body in patients at risk of heart problems. zolsketil pegylated liposomal is used on its own for this disease;• advanced ovarian cancer in women whose previous treatment including a platinum-based cancer medicine has stopped working;• multiple myeloma (a cancer of the white blood cells in the bone marrow), in patients with progressive disease who have received at least one other treatment in the past and have already had, or are unsuitable for, a bone marrow transplantation. zolsketil pegylated liposomal is used in combination with bortezomib (another cancer medicine);• kaposi’s sarcoma in patients with aids who have a very damaged immune system. kaposi’s sarcoma is a cancer that causes abnormal tissue to grow under the skin, on moist body surfaces or on internal organs. zolsketil pegylated liposomal contains the active substance doxorubicin and is a ‘hybrid medicine’. this means that it is similar to a ‘reference medicine’ containing the same active substance called adriamycin. however, in zolsketil pegylated liposomal the active substance is enclosed in tiny fatty spheres called liposomes, whereas this is not the case for adriamycin.
Europska Unija -
hrvatski -
EMA (European Medicines Agency)
onglyza
astrazeneca ab - Саксаглиптин - dijabetes mellitus, tip 2 - lijekovi koji se koriste u dijabetesu - add-on combination therapyonglyza is indicated in adult patients aged 18 years and older with type-2 diabetes mellitus to improve glycaemic control:as monotherapy:in patients inadequately controlled by diet and exercise alone and for whom metformin is inappropriate due to contraindications or intolerance;as dual oral therapy:in combination with metformin, when metformin alone, with diet and exercise, does not provide adequate glycaemic control;in combination with a sulphonylurea, when the sulphonylurea alone, with diet and exercise, does not provide adequate glycaemic control in patients for whom use of metformin is considered inappropriate;in combination with a thiazolidinedione, when the thiazolidinedione alone with diet and exercise, does not provide adequate glycaemic control in patients for whom use of a thiazolidinedione is considered appropriate;as triple oral therapy:in combination with metformin plus a sulphonylurea when this regimen alone, with diet and exercise, does not provide adequate glycaemic control;as combination therapy with insulin (with or without metformin), when this regimen alone, with diet and exercise, does not provide adequate glycaemic control.
Europska Unija -
hrvatski -
EMA (European Medicines Agency)
pritorplus
bayer ag - telmisartan, hydrochlorothiazide - hipertenzija - sredstva koja djeluju na sustav renin-angiotenzina - liječenje esencijalne hipertenzije. pritorplus s fiksnom kombinacijom doze (40 mg телмисартана / 12. 5 mg hidroklorotiazid телмисартан 80 mg / 12. 5 mg hidroklorotiazid) prikazan pacijentima, kod kojih je krvni pritisak nije dovoljno prati na телмисартан sami. pritorplus s fiksnom kombinacijom doza (80 mg телмисартан / hidroklorotiazid 25 mg) prikazan pacijentima, kod kojih je krvni pritisak nije dovoljno prati na pritorplus (80 mg телмисартана / 12. 5 mg hidroklorotiazid) ili bolesnika, koji su prethodno bili su uhvaćeni na телмисартана ili hidroklorotiazid odvojeno.
Europska Unija -
hrvatski -
EMA (European Medicines Agency)
credelio
elanco gmbh - lotilaner - ectoparasiticides za sistemsku primjenu, Изоксазолинов - dogs; cats - za liječenje buha i krpelja zaraženosti. blitve i krpelji moraju se priključiti na domaćina i početi hraniti kako bi bili izloženi aktivnoj tvari. veterinarski medicinski proizvod može se koristiti kao dio strategije liječenja za kontrolu buha alergijskog dermatitisa (fad). dogsthis veterinarskih medicinskih proizvoda osigurava neposredan i otporne ubiti aktivnosti u roku od 1 mjeseca od buha (ctenocephalides feliz i c. Канис) i krpelji (rhipicephalus sanguineus, иксодовых ricinusovog, ja. hexagonus i dermacentor reticulatus). catsthis veterinarskih medicinskih proizvoda osigurava neposredan i jako ubija aktivnost na 1 mjesec protiv buha (ctenocephalides feliz i c. velikog psa) i krpelji (иксодовые ricinusovog).